Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $218.4 million.

  • Altimmune's Liabilities and Shareholders Equity rose 4773.51% to $218.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.4 million, marking a year-over-year decrease of 206.08%. This contributed to the annual value of $139.3 million for FY2024, which is 3386.54% down from last year.
  • Altimmune's Liabilities and Shareholders Equity amounted to $218.4 million in Q3 2025, which was up 4773.51% from $190.4 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Liabilities and Shareholders Equity ranged from a high of $264.3 million in Q1 2021 and a low of $139.3 million during Q4 2024
  • Its 5-year average for Liabilities and Shareholders Equity is $199.3 million, with a median of $205.7 million in 2022.
  • In the last 5 years, Altimmune's Liabilities and Shareholders Equity soared by 38724.97% in 2021 and then plummeted by 3386.54% in 2024.
  • Altimmune's Liabilities and Shareholders Equity (Quarter) stood at $218.9 million in 2021, then fell by 5.45% to $206.9 million in 2022, then rose by 1.79% to $210.6 million in 2023, then crashed by 33.87% to $139.3 million in 2024, then surged by 56.81% to $218.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $218.4 million in Q3 2025, compared to $190.4 million in Q2 2025 and $157.3 million in Q1 2025.